Mixing Nulliparous and Multiparous Women in Randomised Controlled Trials of Preeclampsia Prevention Is Debatable: Evidence from a Systematic Review

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Simon, Emmanuel ^a,b   Caille, Agnès ^a,b,c   Perrotin, Franck ^b   Giraudeau, Bruno ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ DE TOURS   (France)

^c UNIVERSITY HOSPITAL OF TOURS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIOXIDANT; CALCIUM; PHOSPHOLIPID ANTIBODY;

ARTICLE; AUTOIMMUNE DISEASE; BODY MASS; CLINICAL ASSESSMENT; DIABETES MELLITUS; DRUG EFFICACY; FEMALE; HUMAN; HYPERTENSION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MATERNAL AGE; META ANALYSIS; MULTIPARA; NULLIPARA; OUTCOME ASSESSMENT; PREECLAMPSIA; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TWIN PREGNANCY;

FEMALE; HUMANS; PARITY; PRE-ECLAMPSIA; PREGNANCY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84879472130     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066677     Document Type: Article

References (28)

1. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy (2000) Am J Obstet Gynecol. 183: S1-S22.
2. Sibai B, Dekker G, Kupferminc M, (2005) Pre-eclampsia. Lancet 365: 785-799 doi:10.1016/S0140-6736(05)17987-2.
3. Hernández-Díaz S, Toh S, Cnattingius S, (2009) Risk of pre-eclampsia in first and subsequent pregnancies: prospective cohort study. BMJ 338: b2255.
4. Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PFA, (2006) WHO analysis of causes of maternal death: a systematic review. Lancet 367: 1066-1074 doi:10.1016/S0140-6736(06)68397-9.
5. Steer P, (2005) The epidemiology of preterm labour. BJOG 112Suppl 1: 1-3 doi:10.1111/j.1471-0528.2005.00575.x.
6. Duley L, Henderson-Smart DJ, Meher S, King JF (2007) Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev: CD004659. doi:10.1002/14651858.CD004659.pub2.
7. Hofmeyr GJ, Lawrie TA, Atallah AN, Duley L (2010) Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev: CD001059. doi:10.1002/14651858.CD001059.pub3.
8. Rumbold A, Duley L, Crowther CA, Haslam RR (2008) Antioxidants for preventing pre-eclampsia. Cochrane Database Syst Rev: CD004227. doi:10.1002/14651858.CD004227.pub3.
9. Meher S, Duley L (2006) Garlic for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev: CD006065. doi:10.1002/14651858.CD006065.
10. Makrides M, Duley L, Olsen SF (2006) Marine oil, and other prostaglandin precursor, supplementation for pregnancy uncomplicated by pre-eclampsia or intrauterine growth restriction. Cochrane Database Syst Rev: CD003402. doi:10.1002/14651858.CD003402.pub2.
11. Duckitt K, Harrington D, (2005) Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ 330: 565 doi:10.1136/bmj.38380.674340.E0.
12. Macdonald-Wallis C, Lawlor DA, Heron J, Fraser A, Nelson SM, et al. (2011) Relationships of risk factors for pre-eclampsia with patterns of occurrence of isolated gestational proteinuria during normal term pregnancy. PLoS ONE 6: e22115 doi:10.1371/journal.pone.0022115.
13. Gail MH, Benichou J (2000) Encyclopedia of Epidemiologic Methods. Wiley. Chichester.
14. North RA, McCowan LME, Dekker GA, Poston L, Chan EHY, et al. (2011) Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort. BMJ 342: d1875.
15. Luo Z-C, An N, Xu H-R, Larante A, Audibert F, et al. (2007) The effects and mechanisms of primiparity on the risk of pre-eclampsia: a systematic review. Paediatr Perinat Epidemiol 21Suppl 1: 36-45 doi:10.1111/j.1365-3016.2007.00836.x.
16. Walter SD, (1997) Variation in baseline risk as an explanation of heterogeneity in meta-analysis. Stat Med 16: 2883-2900.
17. De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, et al. (2004) Clinical trial registration: a statement from the International Committee of Medical Journal Editors. N Engl J Med 351: 1250-1251 doi:10.1056/NEJMe048225.
18. Verhagen AP, De Vet HC, De Bie RA, Kessels AG, Boers M, et al. (1998) The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol 51: 1235-1241.
19. Askie LM, Duley L, Henderson-Smart DJ, Stewart LA, (2007) Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 369: 1791-1798 doi:10.1016/S0140-6736(07)60712-0.
20. Kent DM, Hayward RA, (2007) Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification. JAMA 298: 1209-1212 doi:10.1001/jama.298.10.1209.
21. Walter SD, (2000) Choice of effect measure for epidemiological data. J Clin Epidemiol 53: 931-939.
22. Kent DM, Rothwell PM, Ioannidis JPA, Altman DG, Hayward RA, (2010) Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal. Trials 11: 85 doi:10.1186/1745-6215-11-85.
23. Rothwell PM, (1995) Can overall results of clinical trials be applied to all patients? Lancet 345: 1616-1619.
24. Kahan BC, Morris TP, (2012) Improper analysis of trials randomised using stratified blocks or minimisation. Stat Med 31: 328-340 doi:10.1002/sim.4431.
25. Lagakos SW, (2006) The challenge of subgroup analyses-reporting without distorting. N Engl J Med 354: 1667-1669 doi:10.1056/NEJMp068070.
26. Julian DG, (2004) Translation of clinical trials into clinical practice. J Intern Med 255: 309-316.
27. Hill CL, LaValley MP, Felson DT, (2002) Discrepancy between published report and actual conduct of randomized clinical trials. J Clin Epidemiol 55: 783-786.
28. Soares HP, Daniels S, Kumar A, Clarke M, Scott C, et al. (2004) Bad reporting does not mean bad methods for randomised trials: observational study of randomised controlled trials performed by the Radiation Therapy Oncology Group. BMJ 328: 22-24 doi:10.1136/bmj.328.7430.22.